ReviewNature reviews. Drug discovery2013
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.
Review in Nature reviews. Drug discovery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 417 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
417 citing papers in PubMed.
- Systems metabolic engineering of a plasmid-freeSynthetic and systems biotechnology · 2027Article
- Discovery of the nucleoside analogue FMAU as a broad-spectrum anti-orthopoxvirus inhibitor in vitro and in vivo using a structure-guided hit expansion strategy.Emerging microbes & infections · 2026Article
- An updated review of enantioselective syntheses and biological actions of carbanucleosides.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Response of the replisome to araA and araC suggests a mechanism for arabinosyl nucleoside tolerance.The EMBO journal · 2026Article
- Triphosphate and diphosphate nucleoside prodrugs: broadening the therapeutic potential of nucleoside-based treatments.RSC medicinal chemistry · 2026Review
- Engineering of a Nucleoside 2'-Deoxyribosyltransferase for Efficient Catalysis of 5-Halogenated-2'-Deoxypyrimidine Nucleosides via Active-Site Channel Expansion.Applied biochemistry and biotechnology · 2026Article
- Subtype-specific clinical significance of RRM1 and RRM2 expression in non-small cell lung cancer: a TCGA-based analysis.Genes & genomics · 2026Article
- Host DNA repair factors empower a mechanism of antiviral nucleoside analog resistance.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Characterization of a Purine Nucleoside Phosphorylase From Colwellia sp. WH041 for Multienzyme Synthesis of Nucleoside Analogs.Chembiochem : a European journal of chemical biology · 2026Article
- Chiral-Modified Nucleoside Analogues: From Bioactivity to Therapeutic Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- Benzodithiolane-Enabled C─O Bond Activation for Deoxygenative Functionalization of Carbohydrates and Nucleosides.Angewandte Chemie (International ed. in English) · 2026Article
- Synthesis of Novel d-Glucopyranuronamide-Based Nucleos(t)ide Analogs Bearing (Triazolyl)methyl Phosph(on)ate Motifs With Anticancer and Antibacterial Potential.ChemMedChem · 2026Article
- AnOrganic letters · 2026Article
- Negative cooperativity drives activity of capsid-directed antivirals against hepatitis B virus.Science advances · 2026Article
- Anomer-Selective Vorbrüggen Reaction for the Catalytic Synthesis of CJournal of the American Chemical Society · 2026Article
- Stereoselective synthesis of 1'-α-cyano carbocyclic pyrimidine nucleoside analogsOrganic & biomolecular chemistry · 2026Article
- Efficient whole-cell biocatalytic synthesis of 2'-deoxy-2'-fluoroadenosine, a key building block for nucleic acid drugs.Synthetic and systems biotechnology · 2026Article
- Host DNA repair factors empower a mechanism of antiviral nucleoside analog resistance.bioRxiv : the preprint server for biology · 2026Article
- Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof-of-Concept Study.ChemMedChem · 2026Article
357 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleoside analogues have been in clinical use for almost 50 years and have become cornerstones of treatment for patients with cancer or viral infections. The approval of several additional drugs over the past decade demonstrates that this family still possesses strong potential. Here, we review new nucleoside analogues and associated compounds that are currently in preclinical or clinical development for the treatment of cancer and viral infections, and that aim to provide increased response rates and reduced side effects. We also highlight the different approaches used in the development of these drugs and the potential of personalized therapy.
Indexed as
Identifiers
23722347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.